Thornburg Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Thornburg Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.46M	Buy	43,061 +32,453	+306%	+$1.78M	0.02%	113
2026 Q1	$599K	Sell	10,608 -80,122	-88%	-$4.67M	0.01%	151
2025 Q4	$5.39M	Buy	90,730 +17,585	+24%	+$957K	0.07%	119
2025 Q3	$3.96M	Sell	73,145 -4,865	-6%	-$278K	0.05%	137
2025 Q2	$4.29M	Sell	78,010 -7,417	-9%	-$437K	0.06%	135
2025 Q1	$6.04M	Sell	85,427 -11,454	-12%	-$771K	0.08%	118
2024 Q4	$6.37M	Sell	96,881 -26	-0%	-$1.74K	0.08%	128
2024 Q3	$6.81M	Sell	96,907 -64,539	-40%	-$5.39M	0.09%	133
2024 Q2	$13.3M	Sell	161,446 -3,546	-2%	-$295K	0.19%	81
2024 Q1	$14.4M	Sell	164,992 -5,810	-3%	-$520K	0.2%	83
2023 Q4	$16.5M	Sell	170,802 -105,276	-38%	-$9.31M	0.24%	69
2023 Q3	$24.4M	Buy	276,078 +18,775	+7%	+$1.67M	0.4%	53
2023 Q2	$22.3M	Buy	257,303 +105,528	+70%	+$9.93M	0.36%	56
2023 Q1	$14.8M	Buy	+151,775	New	+$15.7M	0.24%	75

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Thornburg Investment Management's BMRN Position: Q2 2026 in Review

Thornburg Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 306% in Q2 2026, buying an estimated $1.78M and bringing the position to 43,061 shares worth $2.46M. The position accounts for 0.02% of the portfolio, ranked #113.

Thornburg Investment Management first reported a position in BMRN in Q1 2023 and has held it in 14 quarters since. The position peaked at $24.4M in Q3 2023. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Thornburg Investment Management held 43,061 shares of BioMarin Pharmaceuticals worth $2.46M as of Q2 2026.
Thornburg Investment Management bought 32,453 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.78M.
BioMarin Pharmaceuticals made up 0.02% of Thornburg Investment Management's portfolio in Q2 2026, its #113 holding.
Thornburg Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Thornburg Investment Management's BioMarin Pharmaceuticals position peaked at $24.4M in Q3 2023.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Thornburg Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.